Weiguo Qing
Corporate Officer/Principal presso Hutchison MediPharma Ltd.
Profilo
Weiguo Qing is currently the Vice President & Head-Oncology Research at Hutchison MediPharma Ltd.
He previously worked as a Principal at Abbott Laboratories and Roche Corp.
He holds a doctorate degree from The University of Texas at Austin and a graduate degree from the Institute of Materia Medica.
Posizioni attive di Weiguo Qing
| Società | Posizione | Inizio |
|---|---|---|
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01/01/2008 |
Precedenti posizioni note di Weiguo Qing
| Società | Posizione | Fine |
|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
| Roche Corp. | Corporate Officer/Principal | - |
Formazione di Weiguo Qing
| The University of Texas at Austin | Doctorate Degree |
| Institute of Materia Medica | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| Aziende private | 2 |
|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
| Roche Corp. |
- Borsa valori
- Insiders
- Weiguo Qing
